Elicio reports ELI-002 Phase 1 data: T cell responses correlate with DFS; Phase 2 enrollment expected Q4 2024

Elicio Therapeutics, Inc.

All 12 evaluable patients showed mKRAS-specific T cell responses; RP2D group had 12-fold higher median response vs 1.4 mg group.
T cell response magnitude correlated with DFS: lowest quartile mDFS 3.1 months (p=0.0027), top three quartiles not yet reached.
Antigen spreading in 100% of RP2D-treated patients (n=6); T cells targeted 67.5% of patient-specific neoantigens.
ELI-002 remains safe and well-tolerated; no dose-limiting toxicities or cytokine release syndrome observed.
Phase 2 enrollment expected to complete in Q4 2024; interim event-driven DFS analysis expected H1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.